霜蛎消结胶囊对EMT6乳腺癌小鼠新生血管抑制作用的研究
|
摘要
目的:探究霜蛎消结胶囊治疗乳腺癌的作用机理。方法:取110只ICR雄性小鼠,随机分为荷瘤组、环磷酰胺组、霜蛎消结胶囊高、中、低剂量组,复苏小鼠EMT6乳腺癌细胞株,于小鼠右前腋皮下接种瘤液,接种成功后,霜蛎消结胶囊高、中、低剂量组小鼠给药21 d,环磷酰胺组给药10 d。试验结束后小鼠脱颈处死,称质量,剖离肿瘤并称质量,计算肿瘤生长抑制率;将肿瘤组织HE染色及第Ⅷ因子免疫组织化学染色,观察瘤体内微血管密度及分布;行动脉环实验,观察霜蛎消结胶囊抑制小鼠动脉血管毛细血管支出情况。结果:霜蛎消结胶囊高、中剂量组均能明显抑制移植性小鼠EMT6瘤体的生长,并降低微血管密度(P<0.05);动脉环实验中霜蛎消结胶囊可抑制VEGF诱导的新生血管的形成。结论:霜蛎消结胶囊对小鼠移植性EMT6乳腺癌具有抑制作用,可能的机制为抑制血管新生使肿瘤缩小,而发挥抗肿瘤作用。
Objective: To explore the mechanism of Shuangli Xiaojie Capsule(霜蛎消结胶囊, SLXJC) in the treatment of breast cancer. Methods: A total of 110 ICR male mice were randomly divided into tumor-bearing group, cyclophosphamide group, and high-, middle-, and low-dose groups of SLXJC to resuscitate the mouse EMT6 breast cancer cell line. After inoculation of the tumor fluid, the mice in the high, middle, and low doses of the SLXJC were given 21 days after the inoculation, and the cyclophosphamide group was administered for 10 days. After the end of the test, the mice were sacrificed by cervical dislocation, and the tumor was weighed.The tumor growth inhibition rate was calculated; the tumor tissue was stained with HE and the factor Ⅷ factor immunohistochemical staining was performed to observe the microvessel density in the tumor; the effect of SLXJ capsule on capillary blood vessel expenditure in mice were observed. Results: Both the high and middle doses of SLXJC can significantly inhibit the growth of transplanted mice with EMT6 tumors, and can significantly re-duce the microvessel density(P<0.05); arterial ring experiment in the SLXJC can inhibit the formation of new blood vessels induced by VEGF. Conclusion: SLXJC has inhibitory effects on transplanted EMT6 breast cancer in mice. The possible mechanism may be to inhibit angiogenesis, shrink the tumor and exert antitumor effect.
Objective: To explore the mechanism of Shuangli Xiaojie Capsule(霜蛎消结胶囊, SLXJC) in the treatment of breast cancer. Methods: A total of 110 ICR male mice were randomly divided into tumor-bearing group, cyclophosphamide group, and high-, middle-, and low-dose groups of SLXJC to resuscitate the mouse EMT6 breast cancer cell line. After inoculation of the tumor fluid, the mice in the high, middle, and low doses of the SLXJC were given 21 days after the inoculation, and the cyclophosphamide group was administered for 10 days. After the end of the test, the mice were sacrificed by cervical dislocation, and the tumor was weighed.The tumor growth inhibition rate was calculated; the tumor tissue was stained with HE and the factor Ⅷ factor immunohistochemical staining was performed to observe the microvessel density in the tumor; the effect of SLXJ capsule on capillary blood vessel expenditure in mice were observed. Results: Both the high and middle doses of SLXJC can significantly inhibit the growth of transplanted mice with EMT6 tumors, and can significantly re-duce the microvessel density(P<0.05); arterial ring experiment in the SLXJC can inhibit the formation of new blood vessels induced by VEGF. Conclusion: SLXJC has inhibitory effects on transplanted EMT6 breast cancer in mice. The possible mechanism may be to inhibit angiogenesis, shrink the tumor and exert antitumor effect.
引文
[1]汤钊献,蒋国良,邵志敏,等.现代肿瘤学[M].3版.上海:复旦大学出版社,2014:1019-1021.
[2]陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.
[3] National Cancer Center.Chinese guideline for cancer registration(2016)[M].Beijing:People’s Medical Publishing House,2016:59-75.
[4]邬珊,吴建芳,车向新,等.心钠素抑制血管内皮生长因子刺激的细胞反应及其机制[J].山东医药,2008,48(10):26-27.
[5]李颖博,李宇华,王瑞,等.灵芝多糖对肿瘤细胞与内皮细胞相互作用的影响[J].中国药理学通报,2008,24(2):250-253.
[6]赵澜,张红锋.桑黄粗多糖对肿瘤细胞增殖及转移相关能力的抑制作用[J].华东师范大学学报(自然科学版),2008,2(2):78-84.
[7] Kreisle R A,Ershler W B.Investigation of tumor angiogenesisin an id mouse model:role of host-tumor intevaitions[J].JNatl Cancer nst,1988,80(11):849-854.
[8] Hurvitz S,Mead M.Triple-negative breast cancer:advancements in characterization and treatment approach[J].Curr Opin Obstet Gynecol,2016,28(1):59-69.
[9] Kohler B A,Sherman R L,Howlader N,et al.Annual Report to the Nation on the Status of Cancer,1975-2011,Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,Poverty,and State[J].J Natl Cancer Inst,2015,107(6):048.
[10]江文君.乳腺增生病、乳腺癌前病变和乳腺癌中医证型与p53、C-erb B-2表达差异的相关研究[D].济南:山东中医药大学,2012.
[11]顾锡冬,何若萍,徐光星,等.何仁治疗乳腺癌的用药经验[J].浙江中医杂志,2010,45(10):705-706.
[12] Henry L. M,Liang,Dennis H. T. Chang. Clinical Trials of Chinese Medicine for the Treatment of Cancer[J].Supportive Cancer Care with Chinese Medicine,2010,25(2):271-291.
[13]金雨婷,徐力.乳腺癌中医证型与基因表达关系的研究进展[J].中医药导报,2015,21(4):41-43.
[2]陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2017,26(1):1-7.
[3] National Cancer Center.Chinese guideline for cancer registration(2016)[M].Beijing:People’s Medical Publishing House,2016:59-75.
[4]邬珊,吴建芳,车向新,等.心钠素抑制血管内皮生长因子刺激的细胞反应及其机制[J].山东医药,2008,48(10):26-27.
[5]李颖博,李宇华,王瑞,等.灵芝多糖对肿瘤细胞与内皮细胞相互作用的影响[J].中国药理学通报,2008,24(2):250-253.
[6]赵澜,张红锋.桑黄粗多糖对肿瘤细胞增殖及转移相关能力的抑制作用[J].华东师范大学学报(自然科学版),2008,2(2):78-84.
[7] Kreisle R A,Ershler W B.Investigation of tumor angiogenesisin an id mouse model:role of host-tumor intevaitions[J].JNatl Cancer nst,1988,80(11):849-854.
[8] Hurvitz S,Mead M.Triple-negative breast cancer:advancements in characterization and treatment approach[J].Curr Opin Obstet Gynecol,2016,28(1):59-69.
[9] Kohler B A,Sherman R L,Howlader N,et al.Annual Report to the Nation on the Status of Cancer,1975-2011,Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,Poverty,and State[J].J Natl Cancer Inst,2015,107(6):048.
[10]江文君.乳腺增生病、乳腺癌前病变和乳腺癌中医证型与p53、C-erb B-2表达差异的相关研究[D].济南:山东中医药大学,2012.
[11]顾锡冬,何若萍,徐光星,等.何仁治疗乳腺癌的用药经验[J].浙江中医杂志,2010,45(10):705-706.
[12] Henry L. M,Liang,Dennis H. T. Chang. Clinical Trials of Chinese Medicine for the Treatment of Cancer[J].Supportive Cancer Care with Chinese Medicine,2010,25(2):271-291.
[13]金雨婷,徐力.乳腺癌中医证型与基因表达关系的研究进展[J].中医药导报,2015,21(4):41-43.